Quercis is a biotech company with its main operations in Switzerland which uses a novel new patented technology with its Isoquercetin based investigational drug with the working name KinisoquinTM to prevent thrombus formation by inhibiting protein disulphide isomerase (PDI), a novel antithrombotic therapeutic target in cardiovascular disease. KinisoquinTM is based on a highly purified natural product extract. In a phase 2 multi-center clinical trial in late-stage cancer patients conducted in the United States, the oral administration of 1000 mg daily of Kinisoquin significantly reduced coagulation markers including D-Dimer, P-Selectin and Thrombin generation without evidence of increased risk of hemorrhage (Zwicker et al. JCI Insight 2019). Dr. Stefan Wohlfeil, Chief Medical Officer of Quercis said, "We are hopeful that this drug could be the future of thrombosis prevention in high-risk cancer patients as well as patients at high risk of thrombosis in general. This is a huge step forward as the product is orally administered, safe and has reduced bleeding risk. Preventing thrombosis without increasing the risk of bleeding represents the holy-grail of anticoagulants." Studies have been conducted in collaboration with Harvard, University of Reading, Zurich University Hospital, National Institutes of Health (NIH), as well as other universities and hospital systems in the United States and Europe. Quercis owns a significant number of patents and holds licenses from Harvard, other universities, and the Canadian Government to additional patent properties. For more information: http://www.quercis.com Forward-Looking StatementsThis release includes forward-looking statements regarding Quercis (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors, and the equity markets generally. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Quercis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.